UNSPSC 51141547: Aminobutyric acid

This classification denotes a neurotransmitter, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2ACZ6IPC6I. European Medicines Agency schedules Gamma-aminobutyric acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13946MIG. Gamma-aminobutyric acid generally arises in the molecular formula C4H9NO2. The term 'gamma-aminobutyric acid' is an International Nomenclature of Cosmetic Ingredients designation. SMILES: OC(=O)CCCN.

UNSPSC 51141547 Aminobutyric acid is a Commodity code under which state and local governments procure pharmaceutical products and related health supplies, though recent solicitations show activity focused more broadly on naloxone, drug deactivation systems, generic pharmaceuticals, and OTC products rather than aminobutyric acid specifically. The issuing bodies span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Procurement patterns show health authorities buying finished pharmaceutical products and medical countermeasures for community health, substance-abuse response, and pharmacy benefit programs, with vendors required to meet FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, and standard insurance and employment-verification requirements.

Recent activity centers in Florida and Minnesota, with Texas involvement through a state health commission. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, response deadline July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), proposals due March 26, 2026, with awarded products effective July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The code shows limited recent activity directly under the aminobutyric acid label; most state and local pharmaceutical procurement appears tagged to broader family or class codes or to specific finished-goods commodities rather than this narrow active pharmaceutical ingredient.